Last reviewed · How we verify
Gabob (aminohydroxybutyric acid)
Gabob (generic name: aminohydroxybutyric acid) is a aminohydroxybutyric acid drug. It is currently in unknown development for Epilepsy.
Gabob is thought to work by modulating the activity of certain neurotransmitters in the brain.
Gabob, also known as aminohydroxybutyric acid, is a small molecule drug in the aminohydroxybutyric acid class. Its exact mechanism of action is unknown, but it is FDA-approved for the treatment of epilepsy. The commercial status of Gabob is unclear, and it is not known whether it is patented or available as a generic medication. Further research is needed to fully understand the safety and efficacy of Gabob. As a result, key safety considerations are not well established.
At a glance
| Generic name | aminohydroxybutyric acid |
|---|---|
| Drug class | aminohydroxybutyric acid |
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your brain is a city with many different streets and intersections. Gabob helps to calm down the traffic on these streets by reducing the activity of certain chemical messengers, or neurotransmitters, that can cause seizures. This helps to prevent seizures from occurring.
Approved indications
- Epilepsy
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabob CI brief — competitive landscape report
- Gabob updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Gabob
What is Gabob?
How does Gabob work?
What is Gabob used for?
What is the generic name of Gabob?
What drug class is Gabob in?
What development phase is Gabob in?
Related
- Drug class: All aminohydroxybutyric acid drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Epilepsy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing